Zika Stocks To Watch; $AEMD, $BCRX, $CERS, $INO; Miami-Dade
Mosquitoes Test Positive for Zika
Zika Stocks Added: $OSUR, $SPB
Point Roberts,
WA, September 2, 2016 – Investorideas.com, a global news source and investor
resource covering actively traded sectors including biotech and medical technology
stocks, updates the Zika directory for investors following the sector as news
from The Florida Department of Agriculture and Consumer Services shows test
positive results in Miami-Dade.
Miami-Dade Mosquitoes
Test Positive for Zika
Sep 1, 2016
TALLAHASSEE, Fla. — The Florida Department of Agriculture and Consumer Services
has detected Zika in three mosquito samples from a small area in Miami Beach.
The mosquitoes from Miami Beach that tested positive for Zika are from an area
where increased trapping and intensified mosquito control measures are
occurring due to the investigation of local transmission led by the
Florida.Department of Health. Ninety-five additional samples have been
submitted by Miami-Dade County after the date of the positive submission, and
the mosquitoes have tested negative for Zika.
“This find is
disappointing, but not surprising. Florida is among the best in the nation when
it comes to mosquito surveillance and control, and this detection enables us to
continue to effectively target our resources. Miami-Dade County, the City of
Miami Beach, and state and federal partners will continue to work aggressively
to prevent the spread of Zika,” stated Commissioner of Agriculture Adam H. Putnam.
The Florida
Department of Agriculture and Consumer Services has tested more than 2,470
mosquito samples, consisting of more than 40,000 mosquitoes, since May, and
these three samples are the first to test positive.
Full news:
Zika Virus Stocks
Aethlon Medical, Inc. (NasdaqCM: AEMD) creates innovative medical devices to address life-threatening diseases.
The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology)
establishes the basis for a new class of therapeutics that target the rapid
elimination of disease enabling particles from the circulatory system of
treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a
device that addresses a broad-spectrum of viral pathogens as well as
tumor-secreted exosomes that suppress the immune system of cancer
patients. Aethlon is also operating under two government contracts with
the Defense Advanced Research Projects Agency (DARPA) related the development
of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc.
is a majority owned Aethlon subsidiary that is advancing exosome-based
strategies to diagnose and monitor cancer and infectious disease
progression.
Aethlon Medical (Nasdaq: AEMD) Announces Zika Virus
Data
In vitro studies that demonstrate the rapid capture
of Zika virus by the Aethlon Hemopurifier
SAN DIEGO - August 11, 2016- Aethlon Medical, Inc.
(Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat
infectious disease and cancer, announced today that its researchers have
completed in vitro studies that demonstrate the rapid capture of Zika virus by
the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum
treatment countermeasure against viral pathogens that are untreatable with or
resistant to antiviral drug therapies. At present, the immunotherapeutic
technology is being advanced through an FDA approved human feasibility study.
The Zika studies, which were conducted with small-scale versions of the
Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture
fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood
serum in 5 hours.
The studies were conducted with the Zika viral
strain that has recently spread from South America to ravage Puerto Rico and
likely responsible for the first wave of infections that have begun to occur in
the United States. Zika has been declared a global health threat by the World
Health Organization and is not addressed with a proven drug or vaccine therapy.
According to the CDC, more than 7,300 Americans have been diagnosed with Zika
virus infection, including 1,825 individuals in the continental U.S. and Hawaii.
Researchers have linked Zika virus infection with Guillain-Barre syndrome, a
severe neurological disorder that can cause paralysis. In pregnant women, Zika
can cause Microcephaly, which results in babies being born with a small head
and underdeveloped brain. Zika infection has also been associated with
Arthrogryposis, a condition that results in deformities of joints in the arms
and legs of newborns.
"As a result of our research team's validation
of Zika capture, we have further reinforced the potential of our Hemopurifier®
to be a first line of defense against the growing list of infectious viral
pathogens that are not addressed with traditional drug or vaccine
therapies," stated Aethlon Chairman and CEO, Jim Joyce.
BioCryst Pharmaceuticals (NASDAQ:BCRX) BioCryst Pharmaceuticals designs, optimizes and
develops novel small molecule drugs that block key enzymes involved in rare
diseases. BioCryst’s ongoing development
programs include oral plasma kallikrein inhibitors for hereditary angioedema;
BCX7353 and other second generation compounds, and BCX4430, a broad spectrum
viral RNA polymerase inhibitor. In March the Company announced that results
from a preclinical study of its broad spectrum antiviral BCX4430 in
immune-deficient mice infected with Zika virus would be presented at a World
Health Organization (WHO) meeting scheduled to take place March 7-9 in Geneva,
Switzerland. The primary goal of the study was to assess the effect of BCX4430
treatment on survival through Day 28 in immune-deficient mice infected with the
Zika virus. BCX4430 was administered by intramuscular (I.M.) injection twice a
day beginning four hours prior to virus challenge and continuing for eight
days; two dose levels were tested. In the standard dose BCX4430 group, 7 of 8
mice survived through Day 28. In the low dose BCX4430 group (n=8), and in
control groups administered vehicle placebo (n=8) or ribavirin at two dose
levels (n=16), no animals survived to Day 28. Overall survival for the standard
dose level of BCX4430 was superior to both the placebo and the ribavirin
treatment control groups (p < 0.0001). For both dose levels of BCX4430,
median survival was superior to both control groups (>28 days for BCX4430
standard dose and 23 days for low dose) compared to 14 to 17 days for controls.
This study was conducted at Utah State University, under the ongoing Animal
Models of Infectious Disease Program at the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of Health. This
program provides in vivo screening services for researchers, as part of a
broader suite of preclinical services supported by NIAID. These services are
part of NIAID’s infrastructure for responding to emerging infectious diseases,
such as Zika virus, and allow for research to be quickly directed to support
immediate public health needs.
Cerus Corp. (NasdaqGM:
CERS) is a biomedical products company
focused in the field of blood safety. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in Europe, the
Commonwealth of Independent States, the Middle East and selected countries in
other regions around the world. In the United States, Cerus is seeking regulatory
approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT
red blood cell system is in clinical development
GeneOne Life Science Inc. (KSE:011000.KS; KRX:011000.KR) a
biopharmaceutical company, engages in the research and development of DNA vaccines
to prevent and treat incurable diseases in South Korea and internationally. Its
product pipeline includes VGX-3400, a DNA vaccine, which has completed Phase I
clinical trials for the prevention of avian influenza; VGX-3500, a prophylactic
pre-pandemic influenza DNA vaccine that is in Phase I clinical trials for
protection against swine, avian, and seasonal influenza; and FLUPRIME, a
trivalent influenza vaccine, which is in Phase I clinical trials for the
prevention of the outbreak of seasonal flu. The company is also developing
VGX-6150, a therapeutic DNA vaccine that is in Phase I clinical trials for the
treatment of hepatitis C; and therapeutic DNA vaccines for the treatment of
hepatitis B. In addition, it is involved in the contract manufacturing activities
for various pre-clinical and clinical studies for institutions, universities,
governments, and biotechnology companies. GeneOne Life Science Inc. has a
collaboration with Inovio Pharmaceuticals, Inc. to test and advance a DNA-based
vaccine for preventing and treating the emerging and virulent Zika virus infection. The company was
formerly known as VGX International Inc.
GLAXOSMITHKLINE PLC (NYSE:GSK) creates, discovers, develops, manufactures, and markets pharmaceutical
products, such as vaccines, over-the-counter medicines, and health-related
consumer products worldwide. The company provides pharmaceutical products in
various therapeutic areas, such as respiratory, anti-virals, central nervous
system, cardiovascular and urogenital, metabolic, antibacterials, oncology and
emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It
also offers consumer health products in total wellness, oral care, nutritional,
and skin health areas. In addition, it provides prescription medicines; and
paediatric and adult vaccines against various infectious diseases
Inovio Pharmaceuticals, Inc (NYSE MKT:INO) is
revolutionizing the fight against cancer and infectious diseases. Our
immunotherapies uniquely activate best-in-class immune responses to prevent and
treat disease, and have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of cancer immunotherapies and clinical
studies, the company is advancing a growing product pipeline. Partners and
collaborators include Roche, the University of Pennsylvania, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S. Military HIV
Research Program, US Dept. of Homeland Security, and University of
Manitoba.
Intrexon
Corporation (NYSE:XON) is Powering the Bioindustrial
Revolution with Better DNA™ to create biologically-based products that improve
the quality of life and the health of the planet. The Company's integrated
technology suite provides its partners across diverse markets with
industrial-scale design and development of complex biological systems
delivering unprecedented control, quality, function, and performance of living
cells. We call our synthetic biology approach Better DNA®.
OraSure Technologies, Inc. ( NASDAQ: OSUR), a leader in point of care diagnostic
tests and specimen collection devices has been awarded a contract for up to $16.6
million in total funding from the U.S. Department of Health and Human Services
(HHS) Office of the Assistant Secretary for Preparedness and Response’s
Biomedical Advanced Research and Development Authority (BARDA) to advance the
Company’s rapid Zika tests. The six-year, multi-phased contract includes an
initial commitment of $7.0 million and options for up to an additional $9.6
million to fund the evaluation of additional product enhancements, and clinical
and regulatory activities. The Company is expected to provide an update on
guidance and timing during its next quarterly earnings call in November.
SANOFI-AVENTIS SA
(NYSE:SNY; Paris: SAN.PA) a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. https://lehub.sanofi.com/en/access-healthcare/zika-a-strong-sense-of-urgency/
Spectrum Brands Holdings, Inc. (NYSE: SPB) Spectrum Brands Holdings, a member of the Russell
2000 Index, is a global consumer products company offering an expanding
portfolio of leading brands providing superior value to consumers and customers
every day. The Company is a leading supplier of consumer batteries, residential
locksets, residential builders’ hardware, plumbing, shaving and grooming
products, personal care products, small household appliances, specialty pet
supplies, lawn and garden and home pest control products, personal insect
repellents, and auto care products. Helping to meet the needs of consumers
worldwide, our Company offers a broad portfolio of market-leading, well-known
and widely trusted brands including Rayovac®, VARTA®, Kwikset®, Weiser®,
Baldwin®, National Hardware®, Pfister®, Remington®, George Foreman®, Russell
Hobbs®, Black+ Decker®, Tetra®, Marineland®, Nature’s Miracle®, Dingo®,
8-in-1®, FURminator®, IAMS®, Eukanuba®, Digest-eeze™, Healthy-Hide®,
Littermaid®, Spectracide®, Cutter®, Repel®, Hot Shot®, Black Flag®, Liquid
Fence®, Armor All®, STP® and A/C PRO®. Spectrum Brands' products are sold by
the world's top 25 retailers and are available in more than one million stores
in approximately 160 countries. Based in Middleton, Wisconsin, Spectrum Brands
Holdings generated net sales of approximately $4.69 billion in fiscal 2015. Spectrum Brands, Inc. – Pet, Home &
Garden Division, is a global leader in lawn and garden and home pest control
products, and personal insect repellents. The company offers a broad portfolio
of market-leading, trusted products from brands that include Spectracide®,
Cutter®, Repel®, Hot Shot®, Black Flag® and Liquid Fence®.
About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy,
renewable energy, water stocks, food and beverage (including organic and LOHAS,
wine), defense and security, biotech, technology and mobile. We have also
expanded our global coverage to include Latin American stocks, the Middle East,
sports and entertainment.
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks,
renewable energy, nanotech, defense, technology, biotech and more – use our
stock directories and access them online 24/7 with login as a member to find
your next big idea!
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD - August 11, 2016 - one month of
PR. News publication and social media – two thousand five hundred
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of
each country.
Contact Investorideas.com
800-665-0411
